Despite a recent surge of new molecules achieving regulatory approval after a slump over the last few decades, the pharma industry’s innovation problem is still far from being solved. Finding the next blockbuster still seems harder than ever, despite some recent significant innovations in areas like precision medicine, immunotherapies, cell and gene therapies. The next-level of R&D innovation can be achieved in two main ways: Enhancing human-led, collaborative R&D and also utilizing advanced enabling technologies. Human-led R&D can be driven forward through stronger, smarter collaborations and partnerships with external pharma, biotech and academic institutes. This can include larger scale R&D consortia to pool risks, resources and know-how, as well as public-private partnerships and even open-innovation or crowd sourcing. New models of collaboration need to be explored, attempted and implemented to take advantage of external know-how. Furthermore, in recent years there have been huge advances in technology-enabled innovation such as AI, machine learning, big data, deep data, blockchain or the cloud, supported by robust hardware and IT infrastructure. Such technology, has allowed researchers to both enhance collaboration and achieve fresh insights that are revolutionising R&D intelligence and decision making. This unique event will look at how pharmaceutical and other life science organisations can take advantage of both external and technological innovation to achieve efficiency, productivity and R&D success.

Request agenda here for complete speaker list

PHARMA & BIOTECH

Global Head IT
Bayer, Germany

CEO
BenevolentBio, UK

Vice President, Department Head Innovation & Entrepreneurship Incubator Biopharma
Merck, Germany

Senior Fellow
UCB Celltech, UK

Director Technology Platforms - Global Business Development & Licensing
Sanofi, Germany

Director, Head of UK Open Innovation Neurology Business Group
Eisai Limited, UK

Health Informatics Director,
AstraZeneca, UK

VP, Medical Affairs, Norgine
Excellence Lead, Pinnacle Wellbeing Services, UK

Head of R&D G3O
Janssen, Belgium

Senior Vice President & CSO
Berg Health, USA

Chairman & CEO
United Sciences, LLC, USA

Chief Scientific Officer
ERYTECH Pharma, France

Head of Strategy
Horizon Discovery, UK

Director
Tecrea, UK

Director, Clinical Innovation Department
Janssen, Belgium

 

MEDTECH INDUSTRY & DIAGNOSTICS

Consultant, R&D
BTG International, UK

Senior Vice President Information Technology
Hartmann Group, Germany

Vice President, Head Global Clinical Strategy
Smith & Nephew, Switzerland

Director External Innovation, Oncology Discovery
Roche Diagnostics, Switzerland

Principal Scientist
Abbott Diagnostics, USA

 

ACADEMIC RESEARCH INSTITUTIONS

Director of Business Development Office of Cooperative Research
Yale University, USA

Facility Manager Genomics and Pharmacology, Facility Developmental Therapeutics Branch
NCI/NIH, USA

Co-Director Noncoding RNA Core
Institute for RNA medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, USA

Professor of Pharmaceutical Technologies
University of Greenwich, UK

Group Leader; Head of the Computational Biology and Drug Design group
Inserm, Cancer Research Center of Marseille, France

Thematic Coordinator Molecular Diagnostics Center for Health & Bioresources
Austrian Institute of Technology, Austria

Head of Design and Product Development
Arnhold Institute for Global Health, USA

 

THOUGHT LEADERS & POLICY MAKERS

Executive Director
Pistoia Alliance, UK

Former Head of Health Data & Outcomes
The Association of the British Pharmaceutical Industry (ABPI), UK

Lead Technology Architect, Artificial General Intelligence Inc.
CTO,Richmond AI & Blockchain Consultants (RABC), USA

Founder
Institute for Interdisciplinary Innovation in healthcare, Université Libre de Bruxelles, Belgium

Vice President, Research and Business Development
Quebec Consortium of Drug Discovery, Canada

 

PAYERS & HEALTH TECHNOLOGY ASSESSORS

Chief Innovation Officer
Catalan Agency for Health Quality and Assessment – AquAS

Staff Vice President Corporate Venture Capital
Anthem, Inc.

TECHNOLOGY COMPANIES

Co-Founder
Ctrl Group, UK

Request agenda here for complete speaker list

Pictures from recent R&D Innovation Summit. Imagine being there...

SPEAKER LIST - DAY 1 AM

Executive Director
Pistoia Alliance, UK

Director of Business Development Office of Cooperative Research
Yale University, USA

Global Head IT
Bayer, Germany

CEO
BenevolentBio, UK

Consultant, R&D
BTG International, UK

Chief Innovation Officer
Catalan Agency for Health Quality and Assessment – AquAS

VP, Medical Affairs, Norgine
Excellence Lead, Pinnacle Wellbeing Services, UK

This stream is focused on how the latest R&D technologies can realistically facilitate and accelerate R&D innovation in life sciences. Such technologies include, for example, artificial intelligence, machine learning, big data, deep data, blockchain or the cloud. There is both a lot of promise and a lot of hype surrounding such R&D technologies, so there will be a frank and open discussion of what techs can be realistically taken advantage of today and in the near future or what is not worth the investment and effort. Attendees will learn about how to realise the potential of advanced software, supported by robust hardware infrastructure in order to revolutionise R&D performance and commercial success.
 

SPEAKER LIST - DAY 1 - STREAM1 (PM)

Senior Vice President Information Technology
Hartmann Group, Germany

Director, Clinical Innovation Department
Janssen, Belgium

Co-Founder
Ctrl Group, UK

Senior Vice President & CSO
Berg Health, USA

Facility Manager Genomics and Pharmacology, Facility Developmental Therapeutics Branch
NCI/NIH, USA

Co-Director Noncoding RNA Core
Institute for RNA medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, USA

Health Informatics Director,
AstraZeneca, UK

 

This stream is focused on how pharmaceutical innovation can be enhanced through intelligent and novel external collaborations. Almost all pharma and medtech companies now believe that they key to innovation is not purely through performing R&D in-house, but through partnerships with biotechs, academic or government institutes to tap unique sources of knowledge, capabilities, resources and technologies. However, there are a myriad of different models of external collaborations, which may include classical one-on-one partnerships, but increasingly unique “open-innovation” or partnering with larger-scale R&D consortia to pool risks and resources and know-how. Attendees will hear real life case studies and success stories and learn about what collaborative models, practices and approaches have actually resulted in R&D innovations which promise great commercial success.

SPEAKER LIST - DAY 1 - STREAM 2 (PM)

Head of R&D G3O
Janssen, Belgium

Lead Technology Architect, Artificial General Intelligence Inc.
CTO,Richmond AI & Blockchain Consultants (RABC), USA

Director Technology Platforms - Global Business Development & Licensing
Sanofi, Germany

Former Head of Health Data & Outcomes
The Association of the British Pharmaceutical Industry (ABPI), UK

Staff Vice President Corporate Venture Capital
Anthem, Inc.

 

This stream is focused on how the latest R&D technologies can realistically facilitate and accelerate R&D innovation in life sciences. Such technologies include, for example, artificial intelligence, machine learning, big data, deep data, blockchain or the cloud. There is both a lot of promise and a lot of hype surrounding such R&D technologies, so there will be a frank and open discussion of what techs can be realistically taken advantage of today and in the near future or what is not worth the investment and effort. Attendees will learn about how to realise the potential of advanced software, supported by robust hardware infrastructure in order to revolutionise R&D performance and commercial success.
 

SPEAKER LIST - DAY 2 - STREAM A

Senior Fellow
UCB Celltech, UK

Chief Scientific Officer
ERYTECH Pharma, France

Head of Strategy
Horizon Discovery, UK

Professor of Pharmaceutical Technologies
University of Greenwich, UK

Group Leader; Head of the Computational Biology and Drug Design group
Inserm, Cancer Research Center of Marseille, France

Principal Scientist
Abbott Diagnostic Division, USA

Thematic Coordinator Molecular Diagnostics Center for Health & Bioresources
Austrian Institute of Technology, Austria

Chairman & CEO
United Sciences, LLC, USA

Head of Design and Product Development
Arnhold Institute for Global Health, USA

This stream is focused on how pharmaceutical innovation can be enhanced through intelligent and novel external collaborations. Almost all pharma and medtech companies now believe that they key to innovation is not purely through performing R&D in-house, but through partnerships with biotechs, academic or government institutes to tap unique sources of knowledge, capabilities, resources and technologies. However, there are a myriad of different models of external collaborations, which may include classical one-on-one partnerships, but increasingly unique “open-innovation” or partnering with larger-scale R&D consortia to pool risks and resources and know-how. Attendees will hear real life case studies and success stories and learn about what collaborative models, practices and approaches have actually resulted in R&D innovations which promise great commercial success.

SPEAKER LIST - DAY 2 - STREAM B

Founder
Institute for Interdisciplinary Innovation in healthcare, Université Libre de Bruxelles, Belgium

Vice President, Research and Business Development
Quebec Consortium of Drug Discovery, Canada

Director, Head of UK Open Innovation Neurology Business Group
Eisai Limited, UK

Vice President, Head Global Clinical Strategy
Smith & Nephew, Switzerland

Vice President, Department Head Innovation & Entrepreneurship Incubator Biopharma
Merck, Germany

Director External Innovation, Oncology Discovery
Roche Diagnostics, Switzerland

Director
Tecrea, UK

 

  • Understand what is the ideal mix of people, processes, collaborations, technologies and resources to maximise life science innovation.
  • Leverage the potential of external and collaborative innovation, either through one-on-one partnerships, open-innovation or large R&D consortia.
  • Appreciate how advanced technologies like AI, machine learning, big data, deep data, blockchain or the cloud can be taken advantage of to enhance R&D intelligence and decision making.
  • Learn from thought-leaders and visionaries and network with both scientific and technology experts to have your questions answered to realise the wealth of R&D opportunities.

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Share with Colleagues